Cigna sets aside $3B to boost performance (CI:NYSE)

Bernstein raised its price target for Cigna (NYSE:CI) to $387, citing growth in specialty pharmacy. Cigna set 2026-2030 targets, including 10-14% adjusted earnings growth. Q2 2026 earnings beat expectations, with $7.78 EPS and $71.7B revenue. Analysts have mixed outlooks, with UBS targeting $400 and Evercore ISI at $290.

Cigna (CI) reaffirmed 2026 targets, including $280B revenue and $30.45 EPS. The company will exit the ACA marketplace, cut insurance growth targets, and focus on specialty pharmacy. Shares fell 2% intraday. CI also launched an AI program to reduce medical costs by $200M over three years.

Cigna Group (CI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities • Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.

The Trump administration plans to remove 750,000 ACA enrollees due to alleged fraud, saving $2.2B. Affected individuals include those unaware of enrollments, high earners, and those with employer-provided healthcare. Leading ACA marketplace operators traded lower on the news.

Cigna won a federal appeals court ruling blocking East Coast Advanced Plastic Surgery from suing to collect $3 million in unpaid awards from the No Surprises Act’s dispute-resolution process. The court ruled that the law does not give providers a private right to sue insurers to enforce payments. Cigna has not paid the awards, which were determined through an independent dispute resolution process.